These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 22183108)

  • 1. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
    Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 9. The predictive value of pretherapy [
    Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
    Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
    Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models using comprehensive, lesion-level, longitudinal [
    Santoro-Fernandes V; Schott B; Deatsch A; Keigley Q; Francken T; Iyer R; Fountzilas C; Perlman S; Jeraj R
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3428-3439. PubMed ID: 38795121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?
    Önner H; Abdülrezzak Ü; Tutuş A
    Nucl Med Commun; 2020 Oct; 41(10):1034-1039. PubMed ID: 32516240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
    Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
    Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of peptide receptor radionuclide therapy with
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
    Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
    [No Abstract]   [Full Text] [Related]  

  • 19. The added value of
    Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
    Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP
    Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.